Viruses, viruses, viruses and vaccines.
V4=3x ancestral + 1x BA.5 bivalent
Professor at the Department of Microbiology
Icahn School of Medicine at Mount Sinai
Viruses, viruses, viruses and vaccines.
V4=3x ancestral + 1x BA.5 bivalent
Professor at the Department of Microbiology
Icahn School of Medicine at Mount Sinai
Das Pandemia-Team spricht mit ForscherInnen, ÄrztInnen und alten Bekannten darüber, was sie im Jahr 2022 bewegt, beschäftigt und begeistert hat. Welche wissenschaftlichen Durchbrüche gab es? Welche Krankheiten haben die Welt in Atem gehalten? Sie sprechen unter anderem mit Isabella Eckerle, Mike Ryan, Cornelia Betsch, Florian Krammer und Chikwe Ihekweazu. Klub Pandemia Pandemia Plus bei Apple Podcasts WERBUNG: CHARLES² – PHARMA INSIGHTS (Podcast) Wie wir Arzneimittel entwickeln und verfügbar machen Web | Apple | Spotify Bewerte Pandemia bei Apple Podcasts & Spotify Folge Pandemia bei Mastodon , Twitter & Instagram
@florian_krammer my secondary concern here is that this could functionally result in a reduction of the dose of mRNA-LNPs and limit antigen production in vivo in a manner similar to how memory cells outcompete naive ones for antigen in OAS, which would reduce one of the major advantages of mRNA over other approaches. Moderna did report this in 2019:
Abstract. Accelerated blood clearance (ABC) is a phenomenon in which certain pharmaceutical agents are rapidly cleared from the blood upon second and subsequent
Antibodies that broadly inhibit influenza virus neuraminidase by binding to its active site could be therapeutic candidates, but circulating viruses have acquired a glycosylation site in that region. Here, the authors show that, while the S245N glycosylation site affects binding of tested monoclonal antibodies, protective activity in a mouse model is maintained.
Antibodies that broadly inhibit influenza virus neuraminidase by binding to its active site could be therapeutic candidates, but circulating viruses have acquired a glycosylation site in that region. Here, the authors show that, while the S245N glycosylation site affects binding of tested monoclonal antibodies, protective activity in a mouse model is maintained.